

EFFECTIVENESS AND SAFETY STUDY OF NIVOLUMAB IN SECOND LINE OF ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER




M Camean-Castillo, C. Martinez-Diaz, MD Gil-Sierra, MDP Briceño-Casado, FJ Salmeron-Navas, S. Fenix-Caballero, J Diaz-Navarro, E. Rios-Sanchez, EJ Alegre-DelRey, JM Borrero-Rubio
Hospital Universitario Puerto Real, Cádiz.

PURPOSE

To assess median progression-free survival, overall survival and security in patients diagnosed with advanced nonsquamous non-small cell lung cancer who received second line of treatment with nivolumab monotherapy in our hospital comparing it with the results of the pivotal trial

MATERIAL AND METHODS



RESULTS

25 Patients

2nd Line




80% Male

PS 0 -> 28%

PS 1-> 68%

PS 2-> 4%

There were 2 patients with grade 3 asthenia, 1 patient with alanine aminotransferase increased grade 3 and 1 patient with pneumonitis



CONCLUSION

The effectiveness obtained measured with median progression-free survival was higher than that of the pivotal trial, and analogous measured as overall survival, however we must take into account the limitations of a study with a low number of patients. A small percentage of patients present adverse events grade 3.



L01 - Cytostatics

4CPS-107